CeBIL NNF Collaborative Research Programme Publications

The list covers publications from January 2018 to June 2022 *:

9th Nordic Social Pharmacy Conference 2019. Conference abstracts. (2019). Research in Social and Administrative Pharmacy, (12), doi: 10.1016/j.sapharm.2019.09.006

Aboy M, Crespo C, Liddell K, Minssen T, Liddicoat J. (2019). Mayo's impact on patent applications related to biotechnology, diagnostics and personalized medicine. Nature biotechnology, 37(5), pp. 513-518. doi: 10.1038/s41587-019-0111-5

Aboy M, Liddell K, Crespo C, Cohen IG, Liddicoat J, Gerke S, ... Minssen T. (2019). How does emerging patent case law in the US and Europe affect precision medicine?. Nature biotechnology, 37(10), pp. 1118-1125. doi: 10.1038/s41587-019-0265-1

Aboy M, Crespo C, Liddell K, Davey N, Liddicoat J, Minssen T. (2020). One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?. Nature biotechnology, 38(3), pp. 279-283. doi: 10.1038/s41587-020-0440-4

Aboy M, Liddell K, Liddicoat J, Crespo C, Jordan M. (2021). Mapping the European patent landscape for medical uses of known products. Nature biotechnology, 39(11), pp. 1336-1343. doi: 10.1038/s41587-021-01104-1

Aboy M, Liddell K, Jordan M, Crespo C, Liddicoat J. (2022). European patent protection for medical uses of known products and drug repurposing. Nature biotechnology, 40(4), pp. 465-471. doi: 10.1038/s41587-022-01269-3

Angelis A, Darrow J. (2021). Safeguarding evidence-based decision making in the FDA for COVID-19 vaccines. Vaccine, 39(17), pp. 2328-2330. doi: 10.1016/j.vaccine.2021.03.053

Babic B, Gerke S, Evgeniou T, Cohen IG. (2019). Algorithms on regulatory lockdown in medicine. Science (New York, N.Y.), 366(6470), pp. 1202-1204. doi: 10.1126/science.aay9547

Babic B, Gerke S, Evgeniou T, Cohen IG. (2021). Beware explanations from AI in health care. Science (New York, N.Y.), 373(6552), pp. 284-286. doi: 10.1126/science.abg1834

Babic B, Gerke S, Evgeniou T, Cohen I. (2021). Direct-to-consumer medical machine learning and artificial intelligence applications. Nature Machine Intelligence, (4), doi: 10.1038/s42256-021-00331-0

Beall RF, Hollis A, Kesselheim AS, Spackman E. (2021). Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based?. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(9), pp. 1328-1334. doi: 10.1016/j.jval.2021.04.1277

Beall RF, Kesselheim AS, Hollis A. (2022). Premarket Development Times for Innovative Vaccines--To What Extent Are the Coronavirus Disease 2019 (COVID-19) Vaccines Outliers?. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 74(2), pp. 347-351. doi: 10.1093/cid/ciab389

Beck S, Bergenholtz C, Bogers M, Brasseur T, Conradsen M, Di Marco D, ... Xu S. (2020). The Open Innovation in Science research field: a collaborative conceptualisation approach. Industry and Innovation, (2), doi: 10.1080/13662716.2020.1792274

Belay D, Abate T, Jensen J. (2020). A Montero Auction Mechanism to Regulate Antimicrobial Consumption in Agriculture. American Journal of Agricultural Economics, (5), doi: 10.1002/ajae.12079

Belay D, Jensen J. (2020). ‘The scarlet letters’: Information disclosure and self-regulation: Evidence from antibiotic use in Denmark. Journal of Environmental Economics and Management, doi: 10.1016/j.jeem.2020.102385

Belay D, Jensen J. (2021). Quantitative input restriction and farmers’ economic performance: Evidence from Denmark's yellow card initiative on antibiotics. Journal of Agricultural Economics, (1), doi: 10.1111/1477-9552.12439

Beukel K. (2018). How patent experts create patent breadth. International Journal of Intellectual Property Rights,

Bhaskar S, Tan J, Bogers MLAM, Minssen T, Badaruddin H, Israeli-Korn S, ... Chesbrough H. (2020). At the Epicenter of COVID-19-the Tragic Failure of the Global Supply Chain for Medical Supplies. Frontiers in public health, 8, pp. 562882. doi: 10.3389/fpubh.2020.562882

Boris Babic, I. Glenn Cohen, Theodoros Evgeniou, Sara Gerke. (2020). When Machine Learning Goes Off the Rails. HARVARD BUSINESS REVIEW,

Bostyn S, De Jong T, Poort J, Radauer A. (2018). "Effects of Supplementary Protection Mechanisms for Pharmaceutical Products", Technopolis Group, Report commissioned by the Netherlands Ministries of Health and Economic Affairs and Climate,.

Bostyn S. (2020). Plant Variety Rights Protection and Essentially Derived Varieties: A Fresh Proposal to Untie the Gordian Knot. GRUR International, (8), doi: 10.1093/grurint/ikaa094

Bostyn S. (2020). Personalized Medicine, Intellectual Property Rights and Human Rights. In Torremans P. (Ed.), Intellectual Property and Human Rights  (pp. 907-986). Kluwer Law International.

Bostyn S. (2020). Access to Therapeutics and Vaccines in Times of Health Pandemics: How Exclusivity Rights Can Affect Such Access and What We Can Do About It. Intellectual Property Quarterly, pp. 227-270.

Bostyn S. (2021). Why a COVID IP Waiver Is not a Good Strategy. SSRN Electronic Journal, doi: 10.2139/ssrn.3843327

Bostyn, S.J.R. (2021). Incentivising innovation in life sciences from the 1970s to the present: how complex exclusivity strategies became the standard and what it means for us. In COSTA, C, AURELIO MIRONE, ROBERTO PENNISI, PIERPAOLO M. SANFILIPPO, RUGGERO VIGO. (Ed.), Studi di diritto commerciale per Vincenzo Di Cataldo  (pp. 71-116). Torino: G. Giappichelli Editore.

Bostyn, S.J.R. (2021). Tackling Salami Slicing and Indication Stacking in Orphan Drug Innovation Incentives.

Bradford L, Aboy M, Liddell K. (2020). COVID-19 Contact Tracing Apps: A Stress Test for Privacy, the GDPR and Data Protection Regimes. Journal of Law and the Biosciences, lsaa034, pp. 1-20.

Bradford L, Aboy M, Liddell K. (2020). International transfers of health data between the EU and USA: a sector-specific approach for the USA to ensure an 'adequate' level of protection. Journal of law and the biosciences, 7(1), pp. lsaa055. doi: 10.1093/jlb/lsaa055

Bradford L, Aboy M, Liddell K. (2021). Standard contractual clauses for cross-border transfers of health data after Schrems II. Journal of law and the biosciences, 8(1), pp. lsab007. doi: 10.1093/jlb/lsab007

Cathaoir K, Gunnarsdóttir H, Hartlev M. (2021). The journey of research data: Accessing nordic health data for the purposes of developing an algorithm. Medical Law International, doi: 10.1177/09685332211046179

Celedonia K, Valenti M, Corrales Compagnucci M, Lowery Wilson M. (2020). Community-based health care providers as research participant recruitment gatekeepers: ethical and legal issues in a real-world case example. Research Ethics, (2), doi: 10.1177/1747016120980560

Celedonia K, Corrales Compagnucci M, Minssen T, Lowery Wilson M. (2021). Legal, ethical, and wider implications of suicide risk detection systems in social media platforms. Journal of Law and the Biosciences, (1), doi: 10.1093/jlb/lsab021

Cohen I, Graver H. (2019). A Doctor’s Touch: What Big Data in Health Care Can Teach Us About Predictive Policing. SSRN Electronic Journal, doi: 10.2139/ssrn.3432095

Cohen I, Evgeniou T, Gerke S, Minssen T. (2020). The European artificial intelligence strategy: implications and challenges for digital health. The Lancet Digital Health, (7), doi: 10.1016/S2589-7500(20)30112-6

Cohen I, Minssen T, Price II W, Robertson C, Shachar C. (2022). Volume Introduction. The Future of Medical Device Regulation - Innovation and Protection  (pp. 1-10). Cambridge University Press.

Cohen I. (2020). Informed Consent and Medical Artificial Intelligence: What to Tell the Patient?. SSRN Electronic Journal, doi: 10.2139/ssrn.3529576

Cohen IG, Mello MM. (2018). HIPAA and Protecting Health Information in the 21st Century. JAMA, 320(3), pp. 231-232. doi: 10.1001/jama.2018.5630

Cohen IG, Mello MM. (2019). Big Data, Big Tech, and Protecting Patient Privacy. JAMA, 322(12), pp. 1141-1142. doi: 10.1001/jama.2019.11365

Cohen IG, Adashi EY, Gerke S, Palacios-González C, Ravitsky V. (2020). The Regulation of Mitochondrial Replacement Techniques Around the World. Annual review of genomics and human genetics, 21, pp. 565-586. doi: 10.1146/annurev-genom-111119-101815

Cohen IG, Gerke S, Kramer DB. (2020). Ethical and Legal Implications of Remote Monitoring of Medical Devices. The Milbank quarterly, 98(4), pp. 1257-1289. doi: 10.1111/1468-0009.12481

Corrales Compagnucci M, Forgó N, Kono T, Teramoto S, Vermeulen E. (Ed.), (2019). Legal Tech and the New Sharing Economy. Singapore: Springer Nature.

Corrales Compagnucci M, Meszaros J, Minssen T, Arasilango A, Ous T, Rajarajan M. (2019). Homomorphic Encryption: The ‘Holy Grail’ for Big Data Analytics and Legal Compliance in the Pharmaceutical and Healthcare Sector?. European Pharmaceutical Law Review, (4), doi: 10.21552/eplr/2019/4/5

Corrales Compagnucci M, Minssen T, Seitz C, Aboy M. (2020). Lost on the High Seas without a Safe Harbor or a Shield? Navigating Cross-Border Transfers in the Pharmaceutical Sector After Schrems II Invalidation of the EU-US Privacy Shield. European Pharmaceutical Law Review, (3), doi: 10.21552/eplr/2020/3/5

Corrales Compagnucci M, Aboy M, Minssen T. (2021). Cross-Border Transfers of Personal Data After Schrems II: Supplementary Measures and new Standard Contractual Clauses (SCCs). Nordic Journal of European Law, (2), doi: 10.36969/njel.v4i2.23780

Corrales Compagnucci M, Aboy M, Minssen T. (2021). Cross-Border Transfers of Personal Data after Schrems II: Supplementary Measures and New Standard Contractual Clauses (SCCs). Nordic Journal of European Law, 4(2), pp. 37-47.

Corrales Compagnucci M, Gerke S, Minssen T. (2021). Informed consent during clinical care: A case study for the WHO.

Corrales Compagnucci M, Gerke S, Minssen T. (2021). Discrimination and racial bias in AI technology: A case study for the WHO.

Corrales Compagnucci M, Gerke S, Minnsen T. (2021). Ethics and Governance of Artificial Intelligence for Health : WHO Guidance.

Corrales Compagnucci M. (2019). Big Data, Databases and "Ownership" Rights in the Cloud. Singapore: Springer Nature.

Corrales Compagnucci M., Meszaros J, Minssen T, Arasilango A, Ous T, Rajarajan M. (2019). Homomorphic Encryption: the ‘Holy Grail’ for Big Data Analytics & Legal Compliance in the Pharmaceutical and Healthcare Sector?. European Pharmaceutical Law Review, 3(4), pp. 144-155.

Corrales Compagnucci Marcelo, Haapio Helena, Fenwick Mark. (2022). Research Handbook on Contract Design. United Kingdom: Edward Elgar Publishing Ltd.

Darrow J, Najafzadeh M, Stefanini K, Kesselheim A. (2020). Regulatory approval characteristics of antimicrobial versus non-antimicrobial products, 1984–2018: an evaluation of Food and Drug Administration flexibilities. The Lancet Infectious Diseases, (7), doi: 10.1016/S1473-3099(20)30197-3

Darrow J. (2021). The Perils of Increasing Medicaid Rebates for Drugs With Accelerated Approval. JAMA Health Forum, (10), doi: 10.1001/jamahealthforum.2021.3184

Darrow JJ, Sinha MS, Kesselheim AS. (2018). When markets fail: patents and infectious disease products. Food & Drug Law J, Volume 73(3),

Darrow JJ, Kesselheim AS. (2020). Incentivizing Antibiotic Development: Why Isn't the Generating Antibiotic Incentives Now (GAIN) Act Working?. Open forum infectious diseases, 7(1), pp. ofaa001. doi: 10.1093/ofid/ofaa001

Darrow JJ, Light DW. (2021). Beyond The High Prices Of Prescription Drugs: A Framework To Assess Costs, Resource Allocation, And Public Funding. Health affairs (Project Hope), 40(2), pp. 281-288. doi: 10.1377/hlthaff.2020.00328

Darrow JJ, Dhruva SS, Redberg RF. (2021). Changing FDA Approval Standards: Ethical Implications for Patient Consent. Journal of general internal medicine, 36(10), pp. 3212-3214. doi: 10.1007/s11606-021-06762-0

Darrow JJ. (2021). Government Pharmaceutical Development to Address High Prices: Challenges Ahead. Therapeutic innovation & regulatory science, 55(5), pp. 1103-1105. doi: 10.1007/s43441-021-00324-6

Darrow JJ. (2022). Two views of cancer medicines: Imagery versus evidence. Health marketing quarterly, pp. 1-12. doi: 10.1080/07359683.2021.1997512

de Miguel Beriain I, Minssen T, Chortara T, Duardo Sánchez A, Feeney O, Felzmann H, ... Herrmann J R. (2019). An EU comparative analysis of the regulation of clinical trials supervisory bodies in the aftermath of Regulation 536/2014. European Public Law,

Deb C, Moneer O, Price WN. (2020). Covid-19, single-sourced diagnostic tests, and innovation policy. Journal of law and the biosciences, 7(1), pp. lsaa053. doi: 10.1093/jlb/lsaa053

Dhruva SS, Darrow JJ, Kesselheim AS, Redberg RF. (2022). Experts' Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care. Journal of general internal medicine, doi: 10.1007/s11606-021-07316-0

Dhruva SS, Darrow JJ, Kesselheim AS, Redberg RF. (2022). Strategies to Manage Drugs and Devices Approved Based on Limited Evidence: Results of a Modified Delphi Panel. Clinical pharmacology and therapeutics, 111(6), pp. 1307-1314. doi: 10.1002/cpt.2583

Druedahl LC, Almarsdóttir AB, Kälvemark Sporrong S, De Bruin ML, Hoogland H, Minssen T, ... Sarpatwari A. (2020). A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways. Nature biotechnology, 38(11), pp. 1253-1256. doi: 10.1038/s41587-020-0717-7

Druedahl LC, Lebret A, Minssen T. (2020). ELSI Implications of Prioritizing Biological Therapies in Times of COVID-19. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics, 48(3), pp. 579-582. doi: 10.1177/1073110520958884

Druedahl LC, Minssen T, Price WN. (2021). Collaboration in times of crisis: A study on COVID-19 vaccine R&D partnerships. Vaccine, 39(42), pp. 6291-6295. doi: 10.1016/j.vaccine.2021.08.101

Druedahl LC, Kälvemark Sporrong S, van de Weert M, De Bruin ML, Hoogland H, Minssen T, ... Almarsdóttir AB. (2021). Evolving Biosimilar Clinical Requirements: A Qualitative Interview Study with Industry Experts and European National Medicines Agency Regulators. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 35(3), pp. 351-361. doi: 10.1007/s40259-021-00478-7

Druedahl LC, Kälvemark Sporrong S, Minssen T, Hoogland H, De Bruin ML, van de Weert M, ... Almarsdóttir AB. (2022). Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution. PloS one, 17(1), pp. e0262537. doi: 10.1371/journal.pone.0262537

Druedahl Louise C., De Bruin Marie L., Hoogland Hans, Minssen Timo, van de Weert Marco, Sporrong Sofia Kalvemark, ... Almarsdottir Anna Birna. (2019). MEDICINES AUTHORITY REGULATOR AND INDUSTRY PERCEPTIONS OF BIOSIMILAR INTERCHANGEABILITY.

Gerke S, Kramer DB, Cohen IG. (2019). Ethical and Legal Challenges of Artificial Intelligence in Cardiology. AIMed Magazine, 2(2), pp. 12–17.

Gerke S, Minssen T, Yu H, Cohen I. (2019). Ethical and legal issues of ingestible electronic sensors. Nature Electronics, (8), doi: 10.1038/s41928-019-0290-6

Gerke S, Minssen T & Cohen G. (2020). Ethical and Legal Challenges of Artificial Intelligence-Driven Health Care. In Bohr A, Memarzadeh K. (Ed.), Artificial Intelligence in Healthcare  (pp. 295-336). Academic Press.

Gerke S, Yeung S, Cohen IG. (2020). Ethical and Legal Aspects of Ambient Intelligence in Hospitals. JAMA, 323(7), pp. 601-602. doi: 10.1001/jama.2019.21699

Gerke S, Babic B, Evgeniou T, Cohen IG. (2020). The need for a system view to regulate artificial intelligence/machine learning-based software as medical device. NPJ digital medicine, 3, pp. 53. doi: 10.1038/s41746-020-0262-2

Gerke S, Stern AD, Minssen T. (2020). Germany's digital health reforms in the COVID-19 era: lessons and opportunities for other countries. NPJ digital medicine, 3, pp. 94. doi: 10.1038/s41746-020-0306-7

Gerke S, Shachar C, Chai PR, Cohen IG. (2020). Regulatory, safety, and privacy concerns of home monitoring technologies during COVID-19. Nature medicine, 26(8), pp. 1176-1182. doi: 10.1038/s41591-020-0994-1

Gerke S, Katznelson G, Reiss D, Shachar C. (2021). COVID-19 Antibody Testing as a Precondition for Employment: Ethical and Legal Considerations. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics, 49(2), pp. 293-302. doi: 10.1017/jme.2021.42

Golbus JR, Price WN, Nallamothu BK. (2020). Privacy Gaps for Digital Cardiology Data: Big Problems With Big Data. Circulation, 141(8), pp. 613-615. doi: 10.1161/circulationaha.119.044966

Goodman GR, Kikut A, Bustamante MJ, Mendez L, Mohamed Y, Shachar C, ... Chai PR. (2022). "I'd feel like someone was watchin' me… watching for a good reason": perceptions of data privacy, access, and sharing in the context of real-time PrEP adherence monitoring among HIV-negative MSM with substance use. AIDS and behavior, doi: 10.1007/s10461-022-03614-8

Graber-Soudry O, Minssen T, Nilsson D, Corrales Compagnucci M, Wested J, Illien B. (2021). Legal Interoperability and the FAIR Data Principles: An X-officio study commissioned by the EOSC FAIR Working Group. EOSC Secretariat & X-officio.

Grimpe C, Minssen T, Price II WN, Stern A. (2022). Will mRNA Technology Companies Spawn Innovation Ecosystems?. Harvard Business Review,

Gunnarsdóttir HD, Sinha MS, Gerke S, Minssen T. (2020). Applying the proportionality principle to COVID-19 antibody testing. Journal of law and the biosciences, 7(1), pp. lsaa058. doi: 10.1093/jlb/lsaa058

Gunnarsdóttir HD, Cohen G; Minssen T; Gerke S. (2022). The Ethics and Laws of Medical Big Data. In Marcello I, Pollicino O, Liguori L, Stefanini E, Andorno R. (Ed.), The Cambridge Handbook of Life Science, Information Technology and Human Rights  (pp. 48-55). Cambridge University Press.

Gyawali B, Darrow JJ, Kesselheim AS. (2021). Integrating New Effectiveness Data Into US Food and Drug Administration-Approved Drug Labeling. JAMA internal medicine, 181(7), pp. 897-898. doi: 10.1001/jamainternmed.2021.1994

Harish KB, Price WN, Aphinyanaphongs Y. (2022). Open-Source Clinical Machine Learning Models: Critical Appraisal of Feasibility, Advantages, and Challenges. JMIR formative research, 6(4), pp. e33970. doi: 10.2196/33970

Hey SP, Kesselheim AS, Patel P, Mehrotra P, Powers JH. (2020). US Food and Drug Administration Recommendations on the Use of Surrogate Measures as End Points in New Anti-infective Drug Approvals. JAMA internal medicine, 180(1), pp. 131-138. doi: 10.1001/jamainternmed.2019.5451

Holgersson M, Granstrand O, Bogers M. (2018). The evolution of intellectual property strategy in innovation ecosystems: Uncovering complementary and substitute appropriability regimes. Long Range Planning, (2), doi: 10.1016/j.lrp.2017.08.007

Holman C, Minssen T, Solovy E. (2018). Patentability Standards for Follow-On Pharmaceutical Innovation. Biotechnology Law Report, (3), doi: 10.1089/blr.2018.29073.cmh

Ian T. Liu, Jonathan J. Darrow. (2021). Reconsidering Eradication to Address the Global Infectious Disease Burden. Quinnipiac Health Law Journal, 24(3), pp. 279-325.

Janos Meszaros, Ho C-S, Corrales Compagnucci M. (2019). Nudging Consent & the New Opt-Out System to the Processing of Health Data in England. In Corrales Compagnucci M, Forgó N, Kono T, Teramoto S, Vermeulen E. (Ed.), Legal Tech and the New Sharing Economy  (pp. 61-82). Singapore: Springer Nature.

Jensen Jørgen D., Belay Dagim. (2018). Production- and Sector-Economical Consequences of Reducing Antibiotics' Usage in the Danish Pig Farming (title translated from Danish). Danish Ministry of Environment and Food.

Jensen, Jørgen Dejgård, Belay, Dagim Gashawtena. (2019). Produktions- og sektorøkonomiske konsekvenser af at reducere antibiotikaforbruget i dansk svineproduktion. IFRO.

Joly Y, Dalpé G, Dupras C, Bévière-Boyer B, de Paor A, Dove ES, ... Bombard Y. (2020). Establishing the International Genetic Discrimination Observatory. Nature genetics, 52(5), pp. 466-468. doi: 10.1038/s41588-020-0606-5

Jonathan Darrow, Timo Minssen. (2019). Letter: The Antibiotic Industry Is Broken. London: Economist 2019;431:20.

Jordan M, Liddicoat J, Liddell K. (2021). An empirical study of large, human biobanks: intellectual property policies and financial conditions for access. Journal of Law and the Biosciences, (1), doi: 10.1093/jlb/lsab018

Kannappan S, Darrow JJ, Kesselheim AS, Beall RF. (2021). The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020. Clinical and translational science, 14(5), pp. 1917-1923. doi: 10.1111/cts.13046

Katznelson G, Gerke S. (2021). The need for health AI ethics in medical school education. Advances in health sciences education : theory and practice, 26(4), pp. 1447-1458. doi: 10.1007/s10459-021-10040-3

Kesselheim AS, Darrow JJ, Kulldorff M, Brown BL, Mitra-Majumdar M, Lee CC, ... Avorn J. (2021). An Overview Of Vaccine Development, Approval, And Regulation, With Implications For COVID-19. Health affairs (Project Hope), 40(1), pp. 25-32. doi: 10.1377/hlthaff.2020.01620

Kianzad B, Minssen T. (2018). How Much is Too Much? Defining the Metes and Bounds of Excessive Pricing in the Pharmaceutical Sector. European Pharmaceutical Law Review, (3), doi: 10.21552/eplr/2018/3/5

Klinge UC, Lindgreen N, Minssen T, Valentin A, Brinck-Jensen J, Dokkedahl N, ... Triton Frost T. (2019). AIPPI Report for Denmark on Plausibility in Patent Law: AIPPI 2019 - 2019 Study Questions - Plausibility.

Klugman CM, Dunn LB, Schwartz J, Cohen IG. (2018). Response to Open Peer Commentaries on "The Ethics of Smart Pills and Self-Acting Devices: Autonomy, Truth-Telling, and Trust at the Dawn of Digital Medicine". The American journal of bioethics : AJOB, 18(10), pp. W4-W7. doi: 10.1080/15265161.2018.1514427

Klugman CM, Dunn LB, Schwartz J, Cohen IG. (2018). The Ethics of Smart Pills and Self-Acting Devices: Autonomy, Truth-Telling, and Trust at the Dawn of Digital Medicine. The American journal of bioethics : AJOB, 18(9), pp. 38-47. doi: 10.1080/15265161.2018.1498933

Kongsholm NCH, Christensen ST, Hermann JR, Larsen LA, Minssen T, Pedersen LB, ... Schovsbo J. (2018). Challenges for the Sustainability of University-Run Biobanks. Biopreservation and biobanking, 16(4), pp. 312-321. doi: 10.1089/bio.2018.0054

Kostick-Quenet K, Mandl KD, Minssen T, Cohen IG, Gasser U, Kohane I, ... McGuire AL. (2022). How NFTs could transform health information exchange. Science (New York, N.Y.), 375(6580), pp. 500-502. doi: 10.1126/science.abm2004

Kostick-Quenet KM, Cohen IG, Gerke S, Lo B, Antaki J, Movahedi F, ... Blumenthal-Barby JS. (2022). Mitigating Racial Bias in Machine Learning. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics, 50(1), pp. 92-100. doi: 10.1017/jme.2022.13

Lebret A, Minssen T. (2021). Digital Health, Artificial Intelligence and Accessibility to Health Care in Denmark. European Human Rights Law Review, 2021(1), pp. 39-49.

Lee CC, Darrow JJ, Avorn J, Kesselheim AS. (2020). Origins and Ownership of Remdesivir: Implications for Pricing. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics, 48(3), pp. 613-618. doi: 10.1177/1073110520958890

Lianos I, Minssen T, Kollmar C. (2021). Tackling Grand Challenges with Competition Law: Lessons from the Pandemic. SSRN Electronic Journal, doi: 10.2139/ssrn.3985344

Liddell K, Martin S, Palmer S. (2020). Allocating Medical Resources in the Time of Covid-19 - Letter to the Editor. The New England Journal of Medicine,

Liddell K, Skopek JM, Palmer S, Martin S, Anderson J, Sagar A. (2020). Who gets the ventilator? Important legal rights in a pandemic. Journal of medical ethics, 46(7), pp. 421-426. doi: 10.1136/medethics-2020-106332

Liddell K, Skopek JM, Palmer S, Martin S, Anderson J, Sagar A. (2020). Deciding who gets the ventilator: Will some lives be lost unlawfully?. Journal of Medical Ethics Blog.

Liddell K, Simon DA, Lucassen A. (2021). Patient data ownership: who owns your health?. Journal of law and the biosciences, 8(2), pp. lsab023. doi: 10.1093/jlb/lsab023

Liddell K, Liddicoat, J & Jordan M. (2019). IP policies for large bioresources: the fiction, fantasy, and future of openness. Global Genes, Local Concerns  (pp. 242-263). Edward Elgar Publishing.

Liddicoat J, Liddell K, McCarthy AH, Hogarth S, Aboy M, Nicol D, ... Hopkins MM. (2019). Continental drift? Do European clinical genetic testing laboratories have a patent problem?. European journal of human genetics : EJHG, 27(7), pp. 997-1007. doi: 10.1038/s41431-019-0368-7

Liddicoat J, Liddell K, Aboy M. (2019). The Effects of Myriad and Mayo on Molecular Test Development in the US and Europe: Interviews from the Frontline. SSRN Electronic Journal, doi: 10.2139/ssrn.3381553

Liddicoat J, de Werra J. (2019). When can exclusive licensees initiate patent infringement proceedings?—Lessons for global IP licensing transactions from two recent UK cases. Journal of Intellectual Property Law & Practice, (1), doi: 10.1093/jiplp/jpy159

Liddicoat J, Wested J. (2020). The right recipe for the repurposing omelette. Life Sciences Intellectual Property Review.

Liddicoat J, Liddell K, Fritz Z. (2021). Reconsidering Repositioning Incentives: An Empirical Legal Analysis of Market Protection for New Therapeutic Indications. European Pharmaceutical Law Review, (3), doi: 10.21552/eplr/2021/3/4

Liddicoat J, Liddell K, Aboy M, Wested J. (2021). Has the EU Incentive for Drug Repositioning Been Effective? An Empirical Analysis of the “+1” Regulatory Exclusivity. IIC - International Review of Intellectual Property and Competition Law, (7), doi: 10.1007/s40319-021-01088-0

Liddicoat J, Parish J. (2021). Ironing out the wrinkles: reforms to Crown use and compulsory licensing to help prepare the Patents Act 1977 for the next health crises. Intellectual Property Quarterly, 4, pp. 245-263.

MALIHA G, GERKE S, COHEN I, PARIKH R. (2021). Artificial Intelligence and Liability in Medicine: Balancing Safety and Innovation. The Milbank Quarterly, (3), doi: 10.1111/1468-0009.12504

Matthews D, Brown A, Gambini E, Mc Mahon A, Minssen T, Nordberg A, ... Zimmeren EV. (2021). The Role of Patents and Licensing in the Governance of Human Genome Editing. Queen Mary Law Research Paper No. 364/2021.

Matthews D, Minssen T, Nordberg A. (2022). Balancing Innovation, ‘Ordre Public’ and Morality in Human Germline Editing: A Call for More Nuanced Approaches in Patent Law. European Journal of Health Law, doi: 10.1163/15718093-bja10073

McGahan A, Bogers M, Chesbrough H, Holgersson M. (2020). Tackling Societal Challenges with Open Innovation. California Management Review, (2), doi: 10.1177/0008125620973713

Meszaros J, Corrales Compagnucci M; Minssen T. (2022). The Interaction of the Medical Device Regulation and the GDPR: Do European rules on privacy and scientific research impair the safety & performance of AI medical devices?. In Cohen IG, Minssen T, Price II WN, Robertson C, Shachar V. (Ed.), The Future of Medical Device Regulation : Innovation and Protection  (pp. 77-90). Cambridge University Press.

Minssen T, Schovsbo J. (2018). Big Data in the Health and Life Sciences : What Are the Challenges for European Competition Law and Where Can They Be Found?. Big Data in the Health and Life Sciences : What Are the Challenges for European Competition Law and Where Can They Be Found? Intellectual Property and Digital Trade in the Age of Artificial Intelligence and Big Data. ed. / Xavier Seuba; Christophe Geiger; Julien Pénin. Centre d'études internationales de la propriété intellectuelles (CEIPI), 2018.  (pp. 10).

Minssen T, Van Zimmeren E, Wested J. (2018). Opportunities and challenges for user-generated licensing models in gene-editing. http://blog.petrieflom.law.harvard.edu/,

Minssen T, Bostyn S. (2018). A Ray of Light in Muddy Waters? -The CJEU rules on combination SPCs in C-121/17 Teva v Gilead. European Pharmaceutical Law Review, 2(3), pp. 169-173.

Minssen T, Pierce J. (2018). Big Data and Intellectual Property Rights in the Health and Life Sciences. Big Data, Health Law, and Bioethics  (pp. 311-323). Cambridge University Press.

Minssen T, van Zimmeren E, Wested J. (2018). Clearing a path through the CRISPR patent jungle. Life Sciences Intellectual Property Review (LSIPR), (08-05-2018),

Minssen T, Kesselheim AS, Darrow JJ. (2019). An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?. Nature biotechnology, 37(1), pp. 21-22. doi: 10.1038/nbt.4324

Minssen T, Valentin A, Hajrizaj P. (2019). Denmark. In Berkowitz M, Thompson J, Norton A, Collingwood C, Williams R, Falach A. (Ed.), GLOBAL LEGAL INSIGHTS AI, BIG DATA & MACHINE LEARNING  (pp. 14). Global Legal Insights.

Minssen T, Wested J. (2019). An Update on Research- & Bolar exemptions in the U.S. and Europe: Unsolved questions and new developments in an increasingly important area of law. NIR: Nordiskt Immateriellt Rättsskydd, 2, pp. 168-183.

Minssen T, Seitz C. (2019). Editorial. European Pharmaceutical Law Review, (4), doi: 10.21552/eplr/2019/4/3

Minssen T, Herrmann J, Schovsbo J. (2019). Global Genes, Local Concerns. Edward Elgar Publishing.

Minssen T, Herrmann J R, Schovsbo J. (2019). Global Genes, Local Concerns- Legal, Ethical and Scientific Challenges in International Biobanking. Edward Elgar Publishing.

Minssen T, Herrmann J R, Schovsbo J. (2019). MUCH ADO ABOUT SOMETHING: LEGAL, ETHICAL AND SCIENTIFIC CHALLENGES IN INTERNATIONAL BIOBANKING AND TRANSLATIONAL EXPLOITATION. In Minssen T, Herrmann J R, Schovsbo J. (Ed.), Global Genes, Local Concerns- Legal, Ethical and Scientific Challenges in International Biobanking  (pp. 5). Edward Elgar Publishing.

Minssen T, Seitz C, Aboy M, Corrales Compagnucci M. (2020). The EU-US Privacy Shield Regime for Cross-Border Transfers of Personal Data under the GDPR. European Pharmaceutical Law Review, (1), doi: 10.21552/eplr/2020/1/6

Minssen T, Nordberg A. (2020). Rules and Tools in the Battle Against Superbugs—A Call for Integrated Strategies and Enhanced International Collaboration to Promote Antimicrobial Drug Development. Infectious Diseases in the New Millennium - Legal and Ethical Challenges  (pp. 111-136). Springer International Publishing.

Minssen T, Rajam N, Bogers M. (2020). Clinical trial data transparency and GDPR compliance: Implications for data sharing and open innovation. Science and Public Policy, (5), doi: 10.1093/scipol/scaa014

Minssen T, Mimler M, Mak V. (2020). When Does Stand-Alone Software Qualify as a Medical Device in the European Union?-The Cjeu's Decision in Snitem and What it Implies for the Next Generation of Medical Devices. Medical law review, 28(3), pp. 615-624. doi: 10.1093/medlaw/fwaa012

Minssen T, Outterson K, Rogers Van Katwyk S, Batista PHD, Chandler CIR, Ciabuschi F, ... Hoffman SJ. (2020). Social, cultural and economic aspects of antimicrobial resistance. Bulletin of the World Health Organization, 98(12), pp. 823-823A. doi: 10.2471/blt.20.275875

Minssen T, Gerke S, Aboy M, Price N, Cohen G. (2020). Regulatory responses to medical machine learning. Journal of Law and the Biosciences, lsaa002, pp. 1-18.

Minssen T, Gerke S. (2021). Ethische und rechtliche Herausforderungen digitaler Medizin in Pandemien. Pandemien und Ethik - Entwicklung – Probleme – Lösungen  (pp. 179-219). Springer Berlin Heidelberg.

Minssen T, Aboy M. (2021). The Patentability of Computer-Implemented Simulations and Implications for Computer-Implemented Inventions (CIIs). Journal of Intellectual Property Law & Practice, (7), doi: 10.1093/jiplp/jpab098

Minssen T. (2018). Fair Data Sharing & Data Caring In The Digitalized Era: Aspirations, Realities & Legal Clashes In The Health & Life Sciences.

Minssen T. (2019). ELSI challenges of AI and the Medicus L(ex) Machina. Statens medicinsk-etiska råd (S 1985:A) (Sweden).

Minssen T. (2019). AI in the Health & Life Sciences & the Medicus L(ex) Machina: Setterwalls Life Sciences Report (2019). Setterwalls (Law Firm).

Minssen, Timo, Goldschmieding, Tue ; Sandfeld Jakobsen, Søren. (2020). Denmark. AI, BIG DATA & MACHINE LEARNING – 2020, 2nd EDITION  (pp. 113-128). Global Legal Insights (GLI).

Mitra-Majumdar M, Gunter SJ, Kesselheim AS, Brown BL, Joyce KW, Ross M, ... Darrow JJ. (2022). Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020. JAMA network open, 5(5), pp. e2212454. doi: 10.1001/jamanetworkopen.2022.12454

Moneer O, Brown BL, Avorn J, Darrow JJ, Mitra-Majumdar M, Joyce KW, ... Kesselheim AS. (2022). New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence. Drug safety, 45(4), pp. 305-318. doi: 10.1007/s40264-022-01152-9

Mundkur ML, Franklin J, Huybrechts KF, Fischer MA, Kesselheim AS, Linder JA, ... Patorno E. (2018). Changes in Outpatient Use of Antibiotics by Adults in the United States, 2006-2015. Drug safety, 41(12), pp. 1333-1342. doi: 10.1007/s40264-018-0697-4

Neethu R, Minssen T. (2019). What lurks in the shadows of the openness hyperbole for biopharmaceuticals?. Drug development research, 80(3), pp. 282-284. doi: 10.1002/ddr.21526

Nicol D, Hagger M, Ries N, Liddicoat J. (2019). Time to Get Serious about Privacy Policies: The Special Case of Genetic Privacy. Federal Law Review, (1), doi: 10.22145/flr.42.1.7

Nicol D, Dreyfuss RC, Gold ER, Li W, Liddicoat J, Van Overwalle G. (2019). International Divergence in Gene Patenting. Annual review of genomics and human genetics, 20, pp. 519-541. doi: 10.1146/annurev-genom-083118-015112

Nilsson N, Minssen T. (2018). Unlocking the full potential of open innovation in the life sciences through a classification system. Drug Discovery Today, (4), doi: 10.1016/j.drudis.2018.01.002

Nordberg A, Minssen T, Holm S, Horst M, Mortensen K, Møller BL. (2018). Cutting edges and weaving threads in the gene editing (Я)evolution: reconciling scientific progress with legal, ethical, and social concerns. Journal of law and the biosciences, 5(1), pp. 35-83. doi: 10.1093/jlb/lsx043

Nordberg A, Minssen T, de Miguel Beriain I, Wartiovaara K, Galvagni L, Feeney O. (2018). Response to Nuffield Council on Bioethics’ Genome Editing and Human Reproduction: Open Call for Evidence. Nuffield Council on Bioethics, 28 Bedford Square London WC1B 3JS: Nuffield Council on Bioethics (2018)  (London: Nuffield Council on Bioethics).

Nordberg A, Minssen T, Feeney O, de Miguel Beriain I, Galvagni L, Wartiovaara K. (2020). Regulating germline editing in assisted reproductive technology: An EU cross-disciplinary perspective. Bioethics, 34(1), pp. 16-32. doi: 10.1111/bioe.12705

Panagopoulos A, Minssen T, Sideri K, Yu H, Compagnucci M. (2022). Incentivizing the sharing of healthcare data in the AI Era. Computer Law & Security Review, doi: 10.1016/j.clsr.2022.105670

Polak T, Cucchi D, van Rosmalen J, Uyl-de Groot C, Darrow J. (2022). Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations. Frontiers in Pharmacology, doi: 10.3389/fphar.2022.913567

Polak TB, Cucchi DGJ, Darrow JJ, Versteegh MM. (2022). Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020. BMJ open, 12(4), pp. e058279. doi: 10.1136/bmjopen-2021-058279

Powers JH, Evans SR, Kesselheim AS. (2018). Studying new antibiotics for multidrug resistant infections: are today's patients paying for unproved future benefits?. BMJ (Clinical research ed.), 360, pp. k587. doi: 10.1136/bmj.k587

Pregelj L, Hine D, Kesselheim A, Darrow J. (2021). Assessing the Impact of US Food and Drug Administration Breakthrough Therapy Designation Timing on Trial Characteristics and Development Speed. Clinical Pharmacology & Therapeutics, (4), doi: 10.1002/cpt.2318

Price II WN, Sachs RE, Eisenberg RS. (2022). New Innovation Models in Medical AI. Washington University Law Review, 99, pp. 1121-1173.

Price N. (2019). Medical AI and Contextual Bias. Harvard Journal of Law and Technology, 33(1), pp. 65-116.

Price WN, Gerke S, Cohen IG. (2019). Potential Liability for Physicians Using Artificial Intelligence. JAMA, 322(18), pp. 1765-1766. doi: 10.1001/jama.2019.15064

Price WN, Kaminski ME, Minssen T, Spector-Bagdady K. (2019). Shadow health records meet new data privacy laws. Science (New York, N.Y.), 363(6426), pp. 448-450. doi: 10.1126/science.aav5133

Price WN, Cohen IG. (2019). Privacy in the age of medical big data. Nature medicine, 25(1), pp. 37-43. doi: 10.1038/s41591-018-0272-7

Price WN, Rai AK, Minssen T. (2020). Knowledge transfer for large-scale vaccine manufacturing. Science (New York, N.Y.), 369(6506), pp. 912-914. doi: 10.1126/science.abc9588

Price WN, Rai AK. (2021). Clearing Opacity through Machine Learning. Iowa Law Review, 106, pp. 775-812.

Price WN, Gerke S, Cohen IG. (2021). How Much Can Potential Jurors Tell Us About Liability for Medical Artificial Intelligence?. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 62(1), pp. 15-16. doi: 10.2967/jnumed.120.257196

Price WN. (2018). Big data and black-box medical algorithms. Science translational medicine, 10(471), doi: 10.1126/scitranslmed.aao5333

Price WN. (2021). Problematic Interactions Between AI and Health Privacy. Utah Law Review, 2021, pp. 925-936.

Radziwon A, Bogers M, Chesbrough H, Minssen T. (2021). Ecosystem effectuation: creating new value through open innovation during a pandemic. R&D Management, (2), doi: 10.1111/radm.12512

Rai AK, Price WN. (2021). An administrative fix for manufacturing process patent thickets. Nature biotechnology, 39(1), pp. 20-22. doi: 10.1038/s41587-020-00780-9

Raunig BL, Kesselheim AS, Darrow JJ. (2020). Drug Shortages and the Defense Production Act. American journal of public health, 110(10), pp. 1504-1505. doi: 10.2105/AJPH.2020.305862

Rex JH, Fernandez Lynch H, Cohen IG, Darrow JJ, Outterson K. (2019). Designing development programs for non-traditional antibacterial agents. Nature communications, 10(1), pp. 3416. doi: 10.1038/s41467-019-11303-9

Rome BN, Kesselheim AS. (2020). Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(7), pp. 1671-1675. doi: 10.1093/cid/ciz1039

Schovsbo J, Klinge U, Minssen T. (2018). Reap what you sow!—But what about SPC squatting?. Journal of Intellectual Property Law & Practice, (7), doi: 10.1093/jiplp/jpx229

Schovsbo J, Minssen T, Riis T. (2020). An appraisal of the EU Directive on Trade Secrets. The Harmonization and Protection of Trade Secrets in the EU  (pp. 1-6). Edward Elgar Publishing.

Schovsbo J, Minssen T, Riis T. (2020). An Appraisal of the EU Directive on Trade Secrets. The harmonization and protection of trade secrets in the EU : – An Appraisal of the EU Directive  (pp. 1-7). Edward Elgar Publishing.

Schovsbo Jens, Minssen Timo, Riis Thomas. (2020). The Harmonization and Protection of Trade Secrets in the EU: An Appraisal of the EU Directive. United Kingdom: Edward Elgar Publishing Ltd.

Schovsbo, J, Minssen T, Riis T. (2020). The harmonization and protection of trade secrets in the EU – An Appraisal of the EU Directive. Edward Elgar Publishing.

Shachar C, Gerke S, Adashi EY. (2020). AI Surveillance during Pandemics: Ethical Implementation Imperatives. The Hastings Center report, 50(3), pp. 18-21. doi: 10.1002/hast.1125

Shachar C, Engel J, Elwyn G. (2020). Implications for Telehealth in a Postpandemic Future: Regulatory and Privacy Issues. JAMA, 323(23), pp. 2375-2376. doi: 10.1001/jama.2020.7943

Sherkow J, Minssen T. (2020). AIRR data under the EU Trade Secrets Directive: aligning scientific practices with commercial realities. The Harmonization and Protection of Trade Secrets in the EU  (pp. 237-266). Edward Elgar Publishing.

Sherkow JS, Minssen T. (2018). ANALYSING A COMPLEX RELATIONSHIP: AIRR DATA AND THE E.U. TRADE SECRETS DIRECTIVE. Social Science Research Network (SSRN).

Sinha MS, Powers JH III, Kesselheim AS. (2020). The Wrong Cure: Financial Incentives for Unimpressive New Antibiotics. Journal of Infectious Diseases,

Slokenberga S, Minssen T, Nordberg A. (2022). Governing, Protecting, and Regulating the Future of Genome Editing: The Significance of ELSPI Perspectives. European Journal of Health Law, doi: 10.1163/15718093-bja10076

Spector-Bagdady K, Tang S, Jabbour S, Price WN, Bracic A, Creary MS, ... Wiens J. (2021). Respecting Autonomy And Enabling Diversity: The Effect Of Eligibility And Enrollment On Research Data Demographics. Health affairs (Project Hope), 40(12), pp. 1892-1899. doi: 10.1377/hlthaff.2021.01197

Stern A, Goldfarb A, Minssen T, Price II W. (2022). AI Insurance: How Liability Insurance Can Drive the Responsible Adoption of Artificial Intelligence in Health Care. NEJM Catalyst, (4), doi: 10.1056/cat.21.0242

The Future of Medical Device Regulation - Innovation and Protection. (2022). Cambridge University Press.

Varma M, Almarsdóttir AB, Druedahl LC. (2022). "Biosimilar, so it looks alike, but what does it mean?" A qualitative study of Danish patients' perceptions of biosimilars. Basic & clinical pharmacology & toxicology, 130(5), pp. 581-591. doi: 10.1111/bcpt.13719

Vayena E, Blasimme A, Cohen IG. (2018). Machine learning in medicine: Addressing ethical challenges. PLoS medicine, 15(11), pp. e1002689. doi: 10.1371/journal.pmed.1002689

Victor L. Van de Wiele, Jonathan J. Darrow, Aaron S. Kesselheim. (2021). No Parking Here: A Review of Generic Drug 180-Day Exclusivity and Recent Reform Proposals. Yale Journal of Health Policy, Law, and Ethics, 20, pp. 131-145.

Walsh BS, Darrow JJ, Kesselheim AS. (2022). Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes. Nature biotechnology, 40(2), pp. 167-169. doi: 10.1038/s41587-021-01204-y

Wested J, Minssen T, Van Zimmeren E. (2018). Might the EPO’s Enlarged Board of Appeal step into the CRISPR patent battle and reconsider the “all applicants” approach?. Bill of Health,

Wested J, Minssen T, Van Zimmeren E. (2018). Will the EPO’s Enlarged Board of Appeal hear the Broad's CRISPR case?. Life Sciences Intellectual Property Review (LSIPR),

Wested J, Liddicoat J. (2021). Repositioning for rare diseases - too much, too little or just right?. Nordic Intellectual Property Law Review, 4, pp. 1-20.

Wiens J, Price WN, Sjoding MW. (2020). Diagnosing bias in data-driven algorithms for healthcare. Nature medicine, 26(1), pp. 25-26. doi: 10.1038/s41591-019-0726-6

Yu H. (2018). The European Open Science Cloud and commercialization. Nature biotechnology, 36(12), pp. 1133-1134. doi: 10.1038/nbt.4304

Yu H. (2021). Responsible use of negative research outcomes-accelerating the discovery and development of new antibiotics. The Journal of antibiotics, 74(9), pp. 543-546. doi: 10.1038/s41429-021-00439-w

Yu H. (2021). Digital health technologies under the new EU Medical Devices Regulation: monitoring and governing intended versus actual use. BMJ Innovations, (4), doi: 10.1136/bmjinnov-2021-000713

Yu, H. (2019). Leveraging Research Failures to Accelerate Drug Discovery and Development. Therapeutic Innovation & Regulatory Science,

Zicari R, Brusseau J, Blomberg S, Christensen H, Coffee M, Ganapini M, ... Kararigas G. (2021). On Assessing Trustworthy AI in Healthcare. Machine Learning as a Supportive Tool to Recognize Cardiac Arrest in Emergency Calls. Frontiers in Human Dynamics, doi: 10.3389/fhumd.2021.673104

Ó Cathaoir K, Aasen HS, Gunnarsdóttir HD, Kimmel KM, Lohiniva-Kerkelä M, Rognlien IG, ... Westerhäll LV. (2021). Older Persons and the Right to Health in the Nordics during COVID-19. European journal of health law, pp. 1-28. doi: 10.1163/15718093-bja10052 

* 2022 publications are updated on an ongoing basis, hence the list is not finalized